Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.34

€0.34

-8.570%
-0.03
-8.570%
-

-

 
26.09.24 / Tradegate WKN: A3CN14 / Name: Defence Therapeutics Inc. / Stock / ? /

Defence Therapeutics Inc. Stock

Heavy losses for Defence Therapeutics Inc. today as the stock fell by -€0.030 (-8.570%).
Our community identified positive and negative aspects for Defence Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Defence Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.

Pros and Cons of Defence Therapeutics Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-09

Defence Therapeutics Inc. scheint eine solide finanzielle Leistung zu verzeichnen, gemessen an den vorgelegten Jahresbilanzen. Bei der Analyse der Vermögens-, Cashflow- und Einkommenszahlen wird allerdings klar, dass das Unternehmen trotz offensichtlicher Fortschritte auch einige Herausforderungen zu bewältigen hat.

Die Bilanzen zeigen insgesamt eine beeindruckende Wachstumsdynamik in Bezug auf die Gesamtaktiva von Defence Therapeutics. Von 2020 bis 2022 hat das Unternehmen seinen Wert fast vervierfacht, was auf solides Management und erfolgreiches Wachstum schließen lässt.

Des Weiteren ist der hohe Cashflow besonders erwähnenswert. Im Jahr 2021 verzeichnete das Unternehmen einen positiven Cashflow, der eine robuste finanzielle Gesundheit und Liquidität signalisiert. Eine solide Cash-Position versetzt ein Unternehmen in die Lage, seine kurzfristigen Verbindlichkeiten zu bedienen, zu investieren und eventuelle finanzielle Engpässe besser zu bewältigen.

News

EQS-News: DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
EQS-News: DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
EQS-News: DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
EQS-News: DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
EQS-News: DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
EQS-News: DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
EQS-News: DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
EQS-News: DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
EQS-News: DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM